Oncotype DX not cost-effective for low-risk breast cancer
(HealthDay)—The multigene expression test Oncotype DX (ODX) is not cost-effective for women with breast cancer who are at low risk
Read more
Financial incentives for cholesterol control may be cost-effective
A program that offered financial incentives to both patients and their physicians to control low-density lipoproteins (LDL) cholesterol could be
Read more